EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Using Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients

Ali Emre Bardak iD, Aafeen Mujeeb iD, Ayse Eylul Donmez iD, Nazli Begum Ozturk iD, Eda Yildiz iD, Hemeesh Tandel iD, Merih Deniz Toruner iD, Merve Gurakar iD, Behnam Saberi iD, Nilay Danis iD, Ahmet Gurakar iD

Turkish Journal of Gastroenterology · 13.05.2026

DOI: 10.5152/tjg.2026.26018 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Turkish Journal of Gastroenterology, online erschienen am 13.05.2026. Verfasst von Ali Emre Bardak und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Boston Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Hepatitis B Surface Antigens, Hepatitis B, Tissue Donors. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver transplantation (LT) remains the only definitive treatment for end-stage liver disease and selected hepatic malignancies. However, persistent organ shortages continue to drive high waitlist mortality worldwide. Hepatitis B virus (HBV)-positive donors, including hepatitis B surface antigen (HBsAg)-positive and anti-hepatitis B core antibody–positive (HBsAg negative) donors, represent an increasingly important but historically underused resource. The introduction of high-barrier nucleos(t)ide analogs, the selective use of hepatitis B immunoglobulin, and pre- and posttransplant vaccination have markedly reduced viral transmission, enabling safe transplantation in both HBV-immune and selected HBV-naive recipients. Regional guidelines and consensus statements, including those from the American Society of Transplantation, European Association for the Study of the Liver, American Association for the Study of Liver Diseases, and Asian Pacific Association for the Study of the Liver, support individualized, risk-directed prophylaxis and posttransplant surveillance. Ethical considerations, particularly informed consent and risk–benefit discussions in the setting of organ scarcity, remain central to clinical decision-making. Large cohort studies demonstrate comparable graft and patient survival with HBV-negative grafts, along with economic advantages and expansion of the donor pool. However, evidence in HBV-naive recipients remains limited, with most data derived from immune or previously infected recipients, highlighting the need for careful patient selection and robust prophylaxis. Available evidence on the use of HBsAg-positive donors in HBV-naive recipients is obtained predominantly from cadaveric donor transplantation, as experience with HBsAg-positive living donors remains limited. This narrative review summarizes current evidence on the use of HBsAg-positive grafts in LT, with a focus on HBV-naive recipients, based predominantly on cadaveric donor experience. Cite this article as: Bardak AE, Mujeeb A, Donmez AE, et al. Using hepatitis B surface antigen–positive donors in liver transplantation: Outcomes, prophylaxis, and monitoring with a focus on hepatitis B virus–naive recipients. Turk J Gastroenterol. Published online May 13, 2026. doi: 10.5152/tjg.2026.26018.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationHepatitis B Surface AntigensHepatitis BTissue DonorsEnd Stage Liver DiseaseDonor SelectionHumansHepatitis B virusTreatment Outcome

Stichwörter der Autor:innen

Donors and donationliver transplantationviral hepatitis B

Substanzen

Hepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Internal Medicine, Boston Medical Center, Boston, MA, USA.
  • Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Children's Hospital, University of Illinois, Chicago, USA.
  • Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO, USA.
  • Warren Alpert Medical School of Brown University, RI, USA.
  • Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Ali Emre Bardak, Aafeen Mujeeb, Ayse Eylul Donmez, Nazli Begum Ozturk, Eda Yildiz, Hemeesh Tandel, Merih Deniz Toruner, Merve Gurakar, Behnam Saberi, Nilay Danis, Ahmet Gurakar

Zitieren

APA

Bardak, A. E., Mujeeb, A., Donmez, A. E., Ozturk, N. B., Yildiz, E., Tandel, H., Toruner, M. D., Gurakar, M., Saberi, B., Danis, N., & Gurakar, A. (2026). Using Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2026.26018

Vancouver

Bardak AE, Mujeeb A, Donmez AE, Ozturk NB, Yildiz E, Tandel H, et al. Using Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients. Turkish Journal of Gastroenterology. 2026. doi:10.5152/tjg.2026.26018

BibTeX
@article{Bardak2026,
  author = {Bardak, Ali Emre and Mujeeb, Aafeen and Donmez, Ayse Eylul and Ozturk, Nazli Begum and Yildiz, Eda and Tandel, Hemeesh and Toruner, Merih Deniz and Gurakar, Merve and Saberi, Behnam and Danis, Nilay and Gurakar, Ahmet},
  title = {Using Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients},
  journal = {Turkish Journal of Gastroenterology},
  year = {2026},
  doi = {10.5152/tjg.2026.26018}
}
Kostenlos starten →